Expanding Our Payload-Linker Capabilities with IntoCell

We've partnered with IntoCell Inc. to strengthen our position as a global leader in bioconjugates. Leveraging IntoCell's proprietary drug-linker technologies, we have broadened our offering to further streamline our client's path from concept to clinic.

IntoCell's Proprietary Payload-Linker Technologies

• The OHPAS™ Linker
  • A novel Self-Immolative Group (SIG) with highly flexible cleavage chemistry, dubbed as OHPAS (Ortho Hydroxy-Protected Aryl Sulfate); highly efficacious when conjugated to Camptothecin/Auristatin/Amanitin/PBD/Duocarmycin-based payloads.
• PMT™ Platform
  • A Payload Modification Technology designed to substantially improve the therapeutic index of ADC.
• Novel Camptothecins Payloads: Nexatecan (NxT™) and iso-Nexatecan (iNxT™)

A new series of Camptothecins with a phenol or alcohol function:

• Nexatecan: Compatible with OHPAS
• iso-Nexatecan: Compatible with TBA* and GGFG linkers (*Linker to be announced; applicable to payloads with neutral functional groups)

By integrating IntoCell's innovative technologies with our established expertise in HPAPIs, bioconjugations, and GMP manufacturing, we deliver differentiated, scientifically advanced payload-linker solutions that optimize our client's programs.

Pairing Our Expertise with AJICAP™ to Empower Next-Generation ADCs

We're collaborating with Ajinomoto Bio-Pharma Services to enhance our antibody-drug conjugate (ADC) offering using their advanced, site-specific conjugation technology, AJICAP™. By combining this groundbreaking technology with our extensive ADC expertise, we're helping our partners streamline sophisticated therapies with greater efficacy and precision.

AJICAP™ is a platform of proprietary, site-specific technologies designed to support the development of next-generation ADCs. This technology enables greater precision, binding stability, and flexibility to streamline development timelines and deliver ADCs with reduced toxicity and broader therapeutic windows.

AJICAP™ Site-Specific Conjugation

• Direct chemical site-specific conjugation method for intact native antibodies
• Simplified manufacturing & purification process
• Precise DAR control at specific sites
• Broad compatibility with diverse antibodies & payload-linkers

AJICAP™ Stable & Hydrophilic Linker

• Novel stable & hydrophilic linker, applicable to various payloads
• Increased serum stability & controlled release in cancer tissues
• Minimized ADC aggregation by hydrophilic masking of payloads
• Adaptable to a variety of conjugation technologies, including AJICAP™ conjugation

With this innovative technology now integrated across our global network, we are well-positioned to support next-generation ADC development and manufacture.